Managed Healthcare Executive

CONTINUE TO SITE >

OR WAIT 15 SECS

Autoimmune Diseases Cardiovascular Diseases Eyecare How to Reduce Maternal, Infant Health Risks During COVID-19 Multiple Sclerosis Secondary Progressive Multiple Sclerosis: Patient Impact and Coverage Implications for New Therapies The Improving Patient Access Podcast

Business Strategy Consumers Drug Costs Drug Pipeline Formulary Health Management Health/Disease Strategy Hospitals & Providers Industry Analysis Pharmacy Politics and Policy Practice Management Reimbursement Technology

Autoimmune Diseases Biosimilars Dermatology Diabetes Eyecare HIV Leukemia and Lymphoma Mental Health Obstetrics-Gynecology & Women's Health Oncology Opioids Pediatrics Plaque Psoriasis Solid Tumors Urology

Expert Interviews K-Cast Medical World News Podcasts Population Health Perspectives

Education Sponsored Resources Surveys

eNewsletter Print Subscription

Advertise
Editorial
Contact Us
Terms and Conditions
Privacy
Do Not Sell My Personal Informations

© 2021 MJH Life Sciences and Managed Healthcare Executive. All rights reserved.

Spotlight

Autoimmune Diseases
Cardiovascular Diseases
Eyecare
How to Reduce Maternal, Infant Health Risks During COVID-19
Multiple Sclerosis
Secondary Progressive Multiple Sclerosis: Patient Impact and Coverage Implications for New Therapies
The Improving Patient Access Podcast

BusinessSee All >

Business Strategy
Consumers
Drug Costs
Drug Pipeline
Formulary
Health Management
Health/Disease Strategy
Hospitals & Providers
Industry Analysis
Pharmacy
Politics and Policy
Practice Management
Reimbursement
Technology

ClinicalSee All >

Autoimmune Diseases
Biosimilars
Dermatology
Diabetes
Eyecare
HIV
Leukemia and Lymphoma
Mental Health
Obstetrics-Gynecology & Women's Health
Oncology
Opioids
Pediatrics
Plaque Psoriasis
Solid Tumors
Urology

Advertise
Editorial
Contact Us
Terms and Conditions
Privacy
Do Not Sell My Personal Informations

© 2021 MJH Life Sciences^™ and Managed Healthcare Executive. All rights reserved.

Pleading for reason

February 1, 2002

Health plans demand outcomes-based evidence to support reference pricing for new drug therapies.